The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

MedGenesis Enters Into Agreement with Pfizer for Treatments for PD


(September 29, 2014) - MedGenesis Therapeutix Inc. announced that it has entered into an agreement with Pfizer Inc., granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease. MedGenesis' unique therapeutic approach, delivers GDNF precisely to the regions of the brain where it is required via its CED technology. Read more…



Article Archive

back